Abstract: The present invention relates to the treatment of hemophilia A, in particular to means and methods for subcutaneous administration of Factor VIII (FVIII) proteins. More specifically, the invention relates to FVIII proteins comprising at least one albumin binding domain, which could be shown to have a high bioavailability after subcutaneous administration, in particular, for use in subcutaneous administration to a subject with hemophilia A. The invention also relates to the use of further agents enhancing the bioavailability of FVIII proteins comprising at least one albumin binding domain after subcutaneous administration of such FVIII proteins, in articular human albumin, hyaluronidase and derivatives thereof. The invention also relates to pharmaceutical compositions, combined administration, combined preparations, packages and kits.

Abstract: The present invention relates to the field of immunology, in particular, to the field of modulation of immune responses, in particular, suppression of immune responses and/or induction of tolerance. It provides a tregitope (regulatory T cell activating epitope) carrying polypeptide based on sequences derived from the Fc part of human IgG, wherein said TCP comprises at least one tregitope heterologous to human IgG that is located within at least one of three specific sequence frames. The invention provides such polypeptides for multiple purposes, e.g., in monomeric or dimeric form, wherein both are optionally be linked to an agent, e.g., to which an immune response is to be modulated or suppressed, or co-administered to such an agent, or for use as a stand-alone therapeutic. Nucleic acids encoding the TCP of the invention, pharmaceutic compositions and uses of said TCP are also provided.

Abstract: The present invention relates to a recombinant Factor VIII protein comprising, in a single chain, a heavy chain portion comprising an A1 and an A2 domain and a light chain portion comprising an A3, C1 and C2 domain of Factor VIII, wherein the B-domain is partially deleted in two deletions, the first leading to the presence of a defined processing sequence cleavable by thrombin, and the second leading to absence of the furin cleavage recognition site at position R1664-R1667. An internal fragment of the B-domain is maintained Nucleic acids encoding said protein, host cells and methods of preparing the protein are also provided, as well as a pharmaceutical composition comprising the protein, nucleic acid or host cell, which may be used for treatment of hemophilia A.

Abstract: Postprocessing of medical images (e.g., MRI and CT images) can be facilitated by a variety of techniques, including training methods which include modular organization and/or online presentation, postprocessing protocols which can be used to specify activities which can be predictably and consistently performed by technologists, and deployment of thin client image processing technology. Additional beneficial results relative to what is possible with the prior art can be obtained by combining one or more of the above approaches.